Efficacy of ustekinumab in a patient refractory to other biological treatment
Martin Bortlík Orcid.org 1,2,3, Naděžda Machková Orcid.org 1, Veronika Hrubá1, Martin Lukáš Orcid.org 1, Dana Ďuricová Orcid.org 1, Karin Malíčková Orcid.org 1,4, Zuzana Šerclová Orcid.org 5, Milan Lukáš Orcid.org 1
+ Affiliation
Summary
This case report describes a female patient who was diagnosed at the age of 11 with Crohn’s disease with ileocecal and perianal localization. The disease course was progressive, and conventional therapy was ineffective. The patient did not tolerate long-term treatment with anti-TNF antibodies. Next, therapy with an anti-integrin antibody was given, which had some efficacy for the luminal disease, but none for the perianal disease. Therefore, in June, 2017, we initiated therapy with ustekinumab. The patient responded within 6 weeks, with clear improvement of bowel symptoms as well as perianal disease. We have not observed any adverse effects of ustekinumab in this patient.
Keywords
Crohn’s disease, biologic therapy, ustekinumabTo read this article in full, please register for free on this website.
Benefits for subscribers
Benefits for logged users
Literature
1. Bortlík M. Vývoj léčby IBD v posledních 20 letech. Gastroent Hepatol 2015; 69 (4): 341–350.
2. Lukáš M. Ustekinumab – nová biologická léčba pro pacienty s Crohnovou chorobou. Gastroent Hepatol 2017; 71 (2): 178–180. doi: 10.14735/amgh2017178
3. Feagan BG, Sandborn WJ, Gasink C et al. Ustekinumab as induction and maintenance therapy for Crohn‘s disease. N Engl J Med 2016; 375 (20): 1946–1960.
4. Státní ústav pro kontrolu léčiv. Podmínky úhrady LP Stelara. [online]. Available from: http: //www.sukl.cz/modules/medication/detail.php?kod=0219111.
5. Sands B. Fistula healing in pivotal studies of ustekinumab in Crohn‘s disease. Presented at: Digestive Disease Week 2017. May 6–9, 2017.